GlassScriptPhysician profile
Kamal A Masri
NPI 1134418437
$7,989.34
in general payments reported to CMS, 2019-2025
22 companies · $6,356 in 2025
The $6,356 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $58.86 · 2021: $274 · 2022: $54.55 · 2023: $338 · 2024: $309 · 2025: $6,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,170 · Food and Beverage: $1,636 · Travel and Lodging: $997 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,170.23 |
| Food and Beverage | $1,635.85 |
| Travel and Lodging | $997.47 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,013.47 | 2025 | |
| Abiomed | $634.37 | 2024-2025 | Impella |
| Actelion Pharmaceuticals US, INC. | $348.14 | 2019-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $300.71 | 2025 | |
| Paratek Pharmaceuticals, INC. | $289.58 | 2019-2021 | |
| Glaxosmithkline, LLC. | $216.52 | 2019-2025 | Nucala |
| Mallinckrodt Hospital Products INC. | $160.08 | 2021-2025 | Terlivaz |
| La Jolla Pharmaceutical Company | $134.79 | 2023 | Xacduro |
| Allergan, INC. | $133.26 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $125.00 | 2019 | |
| Insmed, INC. | $113.18 | 2022-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $111.93 | 2019-2025 | Winrevair |
| Erbe USA INC | $100.00 | 2025 | Cryo2 |
| Astrazeneca Pharmaceuticals LP | $93.22 | 2022-2025 | Fasenra |
| Melinta Therapeutics, LLC | $88.58 | 2024-2025 | Orbactiv, Kimyrsa, Rezzayo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $42.28 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.15 | 2023 | Livtencity |
| Regeneron Healthcare Solutions, INC. | $15.64 | 2025 | Dupixent |
| Genzyme Corporation | $14.81 | 2024 | |
| Inari Medical, INC. | $13.47 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Shionogi INC | $12.27 | 2020 | |
| Ambu INC. | $6.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamal Masri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.